Optimal Dose Identification: Proceedings of the Esteve Foundation Symposium IX, Lloret de Mar (Girona), Spain, 4-7 October 2000
These proceedings provide a general update in an important area of clinical pharmacology; describing how individual subjects vary in their response to drugs and how this information can be used to optimise drug dosing in disease. These proceedings cover areas such as the relevance of studies at various stages of drug development, in optimising drug dosing, the role that pharmacokinetics and pharmacodynamics play and how molecular biology has an increasingly important role in this area. As examples of how these influences may play a role, consideration is given to how drug dosing is optimised in various diseases such as cancer, psychiatric and cardiovascular disease, as well as considering the role that age may play in predicting drug dose.
The major theme of this volume is that choosing the optimal dose of a drug has never been more important as risk and benefits must be carefully assessed. There are a series of underlying principles which help determine the optimal dose, and these are dealt with in a systematic manner, using relevant disease states to illustrate these principles.
What people are saying - Write a review
We haven't found any reviews in the usual places.
predicting a safe dose in man from animal
Clinical pharmacology of morphine and morphine6glucuronide
role of phase IV trials
11 other sections not shown
Other editions - View all
2001 Elsevier Science activity acute ADRs adverse drug reactions alleles analgesia antidepressant approach assessment B.V. All rights blood cancer cells changes Clin Clinical Pharmacology clinical trials cognitive function compliance compound covariate cytochrome P450 Danhof depression dosage dose optimisation drug concentrations drug development drug metabolism effect efficacy elderly Elsevier Science B.V. enzyme example exposure factors gene genetic genotype hepatic Holford human hypertension identified increased indinavir individual interactions K.A. Wesnes liver disease measure medication mercaptopurine metabolites methotrexate molecular monoamine morphine noradrenaline opioid optimal oral outcome pain parameter patients pharmacodynamic pharmacokinetics and pharmacodynamics Pharmacol pharmacology phase PK/PD modelling placebo plasma concentrations polymorphism population potential preclinical predict problem propofol protein binding receptor relationship relevant remifentanil renal response ritonavir saquinavir Sheiner SNPs studies target concentration teniposide tests Ther therapeutic drug monitoring therapy toxicity treatment uptake variability variation vitro vivo volunteers W.E. Evans warfarin Wesnes